

IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the claims:

Claim 1 (**currently amended**): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal ~~such as a human~~, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, ~~before, after or simultaneously~~ with an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof.

Claim 2 (**currently amended**): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal ~~such as a human~~, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, ~~before, after or simultaneously~~ with an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof, and before, after or simultaneously with an effective amount of ionising radiation.

Claims 3-4 (**cancelled**).

Claim 5 (**currently amended**): A method for the treatment of a colorectal cancer involving a solid tumour in a warm-blooded animal ~~such as a human~~, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, ~~before, after or simultaneously~~ with an effective amount of ZD6126 or a pharmaceutically acceptable salt thereof.

Claim 6 (**currently amended**): A method for the treatment of a colorectal cancer involving a solid tumour in a warm-blooded animal ~~such as a human~~, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, ~~before, after or simultaneously~~ with an effective amount of ZD6126

or a pharmaceutically acceptable salt thereof, and before, after or simultaneously with an effective amount of ionising radiation.

Claim 7 (**original**): A pharmaceutical composition which comprises AZD2171 or a pharmaceutically acceptable salt thereof, and ZD6126 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient or carrier.

Claim 8 (**original**): A kit comprising AZD2171 or a pharmaceutically acceptable salt thereof, and ZD6126 or a pharmaceutically acceptable salt thereof.

Claims 9-14 (**cancelled**).